{"groups":[{"description":"All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.\n\nPanobinostat, Lenalidomide and Dexamethasone: Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19. Lenalidomide will be given 25 mg: Days 1-21. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.","id":"FG000","title":"Panobinostat, Lenalidomide and Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Non-evaluables"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Progressive Disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment began in July 2012 with enrollment from Sept 2012 to August 2015. 41 subjects signed consent (7 screened failed, 32 received study treatment, 5 non-evaluables). 27 out of the 32 subjects are evaluable."}